Joining forces with a Chinese biologics company enabled Fresenius Kabi to obtain rights up for up to 37 biosimilar candidates over the next decade. Fresenius Kabi, a serious player in the US biosimilar arena, had been seeking ways to bolster its biosimilar pipeline, and it made quite a splash earlier this week. The company signed … Continue reading Fresenius Kabi Expands Biosimilar Pipeline With Deal for Next-Generation Molecules
Tag: Fresenius Kabi
Does the Direct-to-Employer Route for Biosimilars Make Sense?
Employers have strongly indicated that they would like to move away from the big 3 PBMs for cost transparency and the ability to capture as much of the savings as possible themselves. Going the direct-to-employer route, as Waltz Health and Fresenius Kabi are doing, would seem a natural option. Waltz Health, a digital health company, … Continue reading Does the Direct-to-Employer Route for Biosimilars Make Sense?
Biosimilar Bytes: Biocon’s Yesafili Launches and Dr. Reddy’s Rituximab Biosimilar Is Approved
Biocon announced the launch of its Yesafili biosimilar, in competition now with Pavblu, for the aflibercept market. Dr. Reddy’s and its marketing partner Fresenius Kabi have received FDA approval for its rituximab biosimilar. Biocon Begins Marketing Its Aflibercept Biosimilar Yesafili Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Limited, said, “The commercial launch … Continue reading Biosimilar Bytes: Biocon’s Yesafili Launches and Dr. Reddy’s Rituximab Biosimilar Is Approved
Biosimilar Step Therapy for Medicare Part B: Does This Make Sense?
The Centers for Medicare and Medicaid Services (CMS) has decided drugs covered under Medicare part B may be subject to step therapy, if so desired by Medicare Advantage plans. UnitedHealthcare has become the first to publicly implement step therapy policies for these drugs. However, biosimilar step therapy is not the typical utilization management tool that … Continue reading Biosimilar Step Therapy for Medicare Part B: Does This Make Sense?
Fresenius Kabi and Celltrion Get Good News
A German manufacturer is considering its options after the successful completion of two clinical studies involving a pegfilgrastim biosimilar (MSB11455). Fresenius Kabi, which completed its purchase of the biosimilar business from Merck KGaA in September 2017, announced its investigational biosimilar agent had proved sufficiently similar to the reference product Neulasta® in these phase 1 investigations … Continue reading Fresenius Kabi and Celltrion Get Good News